Lampit (nifurtimox) prior authorization
Customize your policy alerts
Sign up for all careoregon policy alerts
Know when careoregon releases new policies or updates existing guidance.
Monitor payer policy activity
Prior authorization requirements for Lampit (nifurtimox) prescribing for members; defines approval length and diagnostic criteria for Chagas disease.
No material clinical or coverage changes in this revision.
Coverage Criteria
Initial Authorization Criteria
Covered when ALL of the following are met
Diagnosed with Chagas disease
- Diagnostic methods: 1) T. cruzi confirmed by detection of T. cruzi trypomastigotes on microscopy OR 2) Detection of T. cruzi DNA by PCR assay
Coverage for Lampit is limited to members with a confirmed diagnosis of Chagas disease. Approval requires documentation of one of the following diagnostic methods: direct visualization of T. cruzi trypomastigotes on microscopy or detection of T. cruzi DNA by PCR assay.
Requests that do not include laboratory confirmation by either microscopy showing T. cruzi trypomastigotes or PCR detection of T. cruzi DNA are at risk for denial. Submit clear diagnostic reports showing the method used and results to support prior authorization.
Provider Actions & Prior Authorization
Prior authorization required for Lampit (nifurtimox)
Prior authorization is required for Lampit (nifurtimox). When approved, the authorization length is 60 days; approval requires a documented diagnosis of Chagas disease as specified in the coverage criteria.
Critical: include required diagnostic confirmation with PA
Ensure all requests include the diagnostic confirmation and documentation specified in policy — missing required diagnostic evidence may lead to denial. Submit prior authorization before dispensing Lampit.
Required diagnostic documentation for approval
Documentation must include evidence of Chagas disease diagnosis by one of the approved methods: either direct detection of T. cruzi trypomastigotes on microscopy or detection of T. cruzi DNA by PCR assay.
- Acceptable evidence: microscopy showing T. cruzi trypomastigotes
- Acceptable evidence: PCR assay detecting T. cruzi DNA
Denial risk: missing diagnostic confirmation
Requests that do not document a confirmed diagnosis of Chagas disease by microscopy detection of T. cruzi trypomastigotes or by detection of T. cruzi DNA by PCR are at risk for denial.
Background
Lampit (nifurtimox) is indicated for the treatment of Chagas disease. This policy establishes prior authorization requirements for Lampit and specifies the documentation needed to demonstrate a qualifying diagnosis. Prior authorization is required and, when approved, the authorization length is 60 days.
Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.